Loading
A phase 3 trial of 5-Aminolevulinic acid in ovarian cancer, run by NX Development Corp, now recruiting.
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) is a phase 3 interventional study registered as NCT05804370 by NX Development Corp, with 170 participants planned, started 2024-05-30 and due to reach its primary completion in 2028-09. Interventions recorded: Gleolan. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares 5-Aminolevulinic acid (oral, for glioma surgery), Fluorescence-guided surgery.
Shares Optical & fluorescence imaging, Fluorescence-guided surgery.
Shares Optical & fluorescence imaging, Fluorescence-guided surgery.
Shares Optical & fluorescence imaging, Fluorescence-guided surgery.
Shares Optical & fluorescence imaging, Fluorescence-guided surgery, Ovarian cancer.
Shares Optical & fluorescence imaging, Fluorescence-guided surgery.
Shares Optical & fluorescence imaging, Fluorescence-guided surgery.
Shares Optical & fluorescence imaging, Fluorescence-guided surgery.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/